Trials / Recruiting
RecruitingNCT05868902
A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients With Suspected Coronary Ischemia.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Genetesis Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter observational data development registry collecting diagnostic measures via standard of care (SOC) cardiac PET in order gain a better understanding of how CardioFlux MCG may be used in the detection of coronary ischemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | CardioFlux Magnetocardiography | The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online) |
Timeline
- Start date
- 2023-08-28
- Primary completion
- 2025-06-01
- Completion
- 2025-12-31
- First posted
- 2023-05-22
- Last updated
- 2025-02-20
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05868902. Inclusion in this directory is not an endorsement.